Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy - A meta-analysis

Acta Oncologica

Volumn 50, Issue 7, 2011, Pages 997-1005

  Sher, Amna ^a   Wu, Shenhong ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM; VASCULOTROPIN ANTIBODY;

ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DATA BASE; DRUG EFFECT; EMBASE; HUMAN; HYPERTENSION; IN SERVICE TRAINING; INCIDENCE; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; META ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SOLID TUMOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ANEMIA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052903751     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.581689     Document Type: Review

References (43)

1. Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400. (Pubitemid 38618122)
2. Genentech. Bevacizumab prescribing information. 2009.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
4. Xue Y, Chen F, Zhang D, Lim S, Cao Y. Tumor-derived VEGF modulates hematopoiesis. J Angiogenes Res 2009;1:9.
5. Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, et al. Anti-VEGF agents confer survival advantages to tumorbearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci USA 2008;105:18513-8.
6. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006;12:793-800. (Pubitemid 44050069)
7. Alexandre I, Billemont B, Meric JB, Richard S, Rixe O. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009;27:472 - 3; author reply 3-4.
8. Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008;26:4047-8.
9. Harshman LC, Kuo CJ, Wong BY, Vogelzang NJ, Srinivas S. Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Cancer Invest 2009;27:851-6.
10. van der Veldt AA, Boven E, Vroling L, Broxterman HJ, van den Eertwegh AJ, Haanen JG. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol 2009;27:1339 - 40; author reply 40-2.
11. Richard S, Croisille L, Yvart J, Casadeval N, Eschwege P, Aghakhani N, et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002;99: 3851-3. (Pubitemid 34534562)
12. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997;127:531-7. (Pubitemid 27419445)
13. NCI [Internet]. National cancer institute's common toxicity criteria (Version 2). [cited 2010 Apr 2]. Available from: http://ctep.cancer.gov/ protocoldevelopment/electronic- applications/docs/ctcv20-4-30-992.pdf .
14. NCI [Internet]. National cancer institute's common toxicity criteria (Version 3.0). [cited 2010 Apr 2]. Available from: http://ctep.cancer.gov/ protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
15. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis. Am J Hypertens Epub 2010 Feb 25 .
16. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008;300:2277-85.
17. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and metaanalysis. Am J Kidney Dis 2007;49:186-93. (Pubitemid 46178407)
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58. (Pubitemid 34746062)
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088-101.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. (Pubitemid 27387172)
22. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370:2103-11. (Pubitemid 350296300)
23. Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, et al. Final analysis of a multi-center, doubleblind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol (Meeting Abstracts) 2007;25(18 suppl):7526.
24. Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB. J Clin Oncol (Meeting Abstracts) 2007;25(18 suppl):4508.
25. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as fi rst-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol (Meeting Abstracts) 2008;26(15 suppl):LBA1011.
26. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27: 2231-7.
27. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as fi rst-line therapy for nonsquamous non-small cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
28. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of effi cacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-50. (Pubitemid 350086476)
29. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
30. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9. (Pubitemid 46224178)
31. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357: 2666-76.
32. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou S-S, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-8.
33. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010;28:2137-43.
34. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14. (Pubitemid 43821788)
35. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24. (Pubitemid 351397066)
36. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A metaanalysis of randomised trials. Lancet 2009;373:1532-42.
37. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009(3):CD007303.
38. Amgen [Internet]. Epogen (Epoetin alpha) for injection. [cited 2010 Jul 21]. Available from: http://pi.amgen.com/ united-states/epogen/epogen-pi-hcp- english.pdf
39. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-45. (Pubitemid 40767935)
40. Munugalavadla V, Kapur R. Role of c-Kit and erythropoietin receptor in erythropoiesis. Crit Rev Oncol Hematol 2005;54: 63-75. (Pubitemid 40387006)
41. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
42. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - A review on pharmacology, metabolism and side effects. Curr Drug Metab Epub 2009 Jun 1.
43. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91:2214-21. (Pubitemid 32552805)